【レポートの概要(一部)】
1. Report Overview
1.1 Overview of the World Market for Macular Degeneration and Other Retinal Diseases
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who Is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain
2. World AMD and Other Disease Market, 2015
2.1 What are Retinal Diseases?
2.2 Types of Retinal Diseases
2.3 Diagnostics and Treatments for AMD and Other Retinal Diseases
2.4 Nearly 200 Million People with AMD?
2.5 Over 100 Million with DR
2.6 First RVO Estimates Suggest Patient Population of 16 Million
2.7 Market to Make Rapid Pace to 2026
2.8 Eylea Became Leading drug in the Market
2.9 Regeneron the Leading Presence in the Market
2.10 Which are the Most Significant Disease Areas for the Market?
3. Retinal Disease Market Subsectors, 2015
3.1 Wet AMD Still the Main Source of Revenue in the Market
3.2 Wet AMD: Angiogenic Processes Offer Well-Defined Drug Targets
3.2.1 Revenue Forecasting for Wet AMD segment, 2015-2026
3.3 Dry AMD: Unmet Need to Arrest or Reverse Damage to RPE
3.3.1 Dry AMD Segment to Emerge in the Forecast Period
3.4 DR: Coming Into Clinical Focus, with DME the Main Target
3.4.1 Segment to Grow in Importance as Diabetes Epidemic Continues
3.5 Lucentis and Eylea Label Extensions Highlight Possibilities in Other Disease Areas
3.6 Projections for All Segments, 2015-2026
4. Approved Products in the AMD and Other Retinal Diseases Market, 2015-2026
4.1 Will the Current Products Dominate the Market Through 2026?
4.2 Lucentis: Second Leading Drug in the Market
4.2.1 Positive Revenue Growth Shown in Past: 2012-2015
4.2.2 Shadow of Avastin Still Hangs Over Lucentis
4.2.3 CATT Study Results: Clinical Differences Still Have Yet to Emerge
4.2.4 Eylea: The Bigger Threat to Lucentis? (might shift in eylea section)
4.2.5 Extending the Label, Widening the Battleground: Lucentis Moves Into DME and Beyond
4.2.6 Improving Cost and Compliance for Lucentis
4.2.7 Lucentis Revenue Forecast 2015-2026
4.2.8 Will Loss of Physician Goodwill Harm Lucentis’ Growth?
4.3 Eylea: Holds the Throne?
4.3.1 Increasing Revenue Growth in Past: Outside US Sale Amplified
4.3.2 VIEW 1 and VIEW 2: Is Eylea Superior or Just Non-Inferior to Lucentis?
4.3.3 First Wave of Eylea’s Expansion Finally Beginning to Break?
4.3.4 Eylea into DME and Other New Indications
4.3.5 Eylea Revenue Forecast 2015-2026
4.3.6 How Far Can Eylea’s Momentum Carry It?
4.4 Avastin: No Formal wAMD Approval but Still the Most-Used Product
4.4.1 Past Revenue illustrates Increasing Use of Avastin for wetAMD
4.4.2 Judicial Review Averted in the UK by Price Adjustment
4.4.3 Multiple Attempts to Block Off-Label Avastin Since 2007
4.4.4 Roche and Novartis Challenge CATT’s Headline Conclusions
4.4.5 Will Eylea/Zaltrap Affect Avastin’s Place in the Market?
4.4.6 Avastin Revenue Forecast, 2015-2026
4.4.7 Will Anything Dislodge Avastin from its Central Position?
4.5 Visudyne (Valeant/Novartis): Declining Sales throughout the Forecast Period
4.5.1 Visudyne Revenue Forecast, 2015-2026
4.6 Jetrea (ThromboGenics/Novartis): Disappointing Launch in 2013
4.6.1 Jetrea Revenue Forecast, 2015-2026
5. Pipeline for Wet AMD Segment, 2015-2026
5.1 The Leading Pipeline Candidates
5.2 Fovista (Ophthotech Corporation/Novartis): The Next Big Thing?
5.2.1 Three Phase 3 Trials to Confirm Fovista’s Outstanding Phase 2 Results
5.2.2 Ophthotech Goes Public to Fund Phase 3 Effort
5.2.3 Ophthotech Partners with Novartis for Fovista
5.2.4 Improving Angiogenesis Inhibition by Blocking Pericyte Recruitment
5.2.5 The Move toward Combination Therapies
5.3 Other Growth Factor Targets in the Pipeline
5.3.1 Squalamine (OHR Pharmaceutical): Combination Targeting in a Single Eyedrop
5.3.2 Allergan and Molecular Partners: Preclinical DARPin Hits VEGF and PDGF
5.3.3 NT-506 (Neurotech Pharmaceutical): Sustained-Release VEGF/PDGF Options
5.3.4 iSONEP (Lpath): Pfizer Interested in Anti-S1P Monoclonal Antibody
5.4 Conbercept (Chengdu Kanghong Biotech): The Other Phase 3 Candidate in wAMD
5.4.1 A Chinese Competitor: Where Will Conbercept Fit In?
5.4.2 Binding Affinity Comparable to Eylea
5.5 Do We Need New Anti-VEGFR Agents or Delivery Systems?
5.5.1 Abicipar Pegol (Allergan): Novel Protein with Extended Half-Life
5.5.2 Brolucizumab (Alcon): Single-Chain Monoclonal Antibody Fragment
5.5.3 PDS 1.0 (ForSight Vision4): A New Option for Lucentis Delivery
5.5.4 NT-503 (Neurotech): New Delivery Platform for Anti-VEGF Agent
5.5.5 Pan-90806 (PanOptica): Anti-VEGF Eyedrop in Preclinical Development
5.5.6 Iontophoretic Delivery: EyeGate Pharmaceuticals Leading the Way
5.6 Novel Delivery Systems to Rejuvenate Anti-Inflammatory Approaches
5.6.1 Verisome System and IBI-30089 (Icon Bioscience)
5.6.2 CPC-551 (Colby Pharmaceutical): An Alternative Anti-Inflammatory Approach?
5.7 Other Targets Under Investigation in wAMD Drug Development
5.7.1 Are Kinase Inhibitors Still a Going Concern in wAMD?
5.7.2 Pazopanib (GlaxoSmithKline) and TG100801 (Sanofi): Two Eyedrop Kinase Inhibitors Drop Out of the Running
5.7.3 X-82 Pill (Tyrogenex): Dual Kinase Inhibitor
5.7.4 Factor C5: A More Promising Target Addressed by Zimura (Ophthotech) and LFG316 (Novartis)
5.7.5 Integrins: Another Blockable Component of the Neovascularisation Cascade?
5.7.6 Luminate (Allegro Ophthalmics): Novel Anti-Integrin Oligopeptide
5.7.7 Jetrea (ThromboGenics/Novartis): Can Pharmacologic Vitreolysis Help wAMD Patients?
5.7.8 Novel Anti-Angiogenic Treatments in Development: Ora Bio’s ORA102 and CoMentis’ ATG003
5.7.9 Zybrestat (Oxigene): New Mechanism of Action Offers Way to Disrupt Neovascularisation
5.7.10 Synthetic Biologies: Oligonucleotides and SiRNAs for wAMD
5.8 Regenerative Medicine Approaches
5.8.1 Allogeneic Stem Cells (Mesoblast): Potential Synergistic Treatment for Use alongside Lucentis
5.8.2 AVA-101 and AVA-201(Avalanche Biotechnologies): Ocular BioFactory for wAMD
5.8.3 RetinoStat (Oxford BioMedica): LentiVector Technology to Deliver Anti-Angiogenic Genes
6. Pipeline for Dry AMD Segment, 2015-2026
6.1 Who Will Achieve the Big Breakthrough in Dry AMD?
6.2 MC-1101 (MacuCLEAR): Leading the Pack?
6.2.1 Increasing Choroidal Blood Flow with Repurposed Product
6.2.2 Novel Endpoints in Phase 3 Study
6.2.3 Can MacuCLEAR Make It?
6.3 ACU-4429 (Acucela): Visual Cycle Modulator in Phase 3
6.3.1 Data Expected in July 2016
6.3.2 Other Visual Cycle Modulators
6.4 High Hopes for Complement Inhibition in Dry AMD
6.4.1 Lampalizumab (Roche): The Big News of ARVO 2013
6.4.2 MAHALO Study Indicates GA Progression Slowed by Lampalizumab
6.5 Corticosteroids: Targeting Inflammation’s Role in Dry AMD Pathogenesis
6.5.1 Iluvien (Alimera Sciences): Study terminated
6.5.2 AGN208397 (Allergan): New Potent Steroid Expected to Undergo Trials in Dry AMD
6.6 Neuroprotection: One of Modern Medicine’s Holy Grails
6.6.1 Tandospirone (Alcon): Not effective in GA
6.6.2 Renexsus (Neurotech): Possibly Promising Data in Dry AMD Studies
6.6.3 Novadur (Allergan): Possible Efficacy with Longer Duration of Action
6.6.4 VAR10200 (Varinel): A Preclinical Candidate to Watch
6.7 Regenerative Medicine: Dry AMD One of the Biggest Disease Targets
6.7.1 MA09-hRPE Cellular Therapy (Ocata Therapeutics): Signs of Efficacy in Landmark ESC Human Trial
6.7.2 HuCNS-SC (StemCells): Leading Company in Neural Stem Cell Space
6.7.3 Stemedyne-RPE (Stemedica Cell Technologies): Low-Oxygen Cells for Dry AMD Repair
6.7.4 OpRegen (Biotime): Stem Cell leader with Dry AMD Interests
6.7.5 First iPSC Trial in Japan in Dry AMD Patients
6.7.6 Gene Therapies Less Prominent Than Stem Cells in Dry AMD
6.8 Other Treatments for Dry AMD
7. Pipeline for Diabetic Retinopathy Segment, 2015-2026
7.1 Ozurdex/Posurdex (Allergan): Approved for General DME Patient Population
7.2 Lucentis: The Game Changer for DR?
7.3 New Anti-VEGF Additions
7.3.1 Is Eylea Better than Lucentis and Avastin for DME?
7.4 Steroids in Development for DR
7.4.1 Iluvien (Alimera/pSivida): New Option in European Markets
7.4.2 A New Hope? Optina (Ampio Pharmaceuticals)
7.4.3 Betamethasone Microsphere (Santen): Late-Stage Steroid Candidate
7.4.4 Cortiject (Santen): Prodrug Candidate
7.4.5 IBI-20089 (Icon Bioscience): Sustained-Release Formulation of Triamcinolone Acetonide
7.5 Other Products in Development for DR
7.5.1 Angiotensin Receptor Blockers/Angiotensin-Converting Enzyme Inhibitors: Some Off-Label Validation
7.5.2 Vitreosolve (Innovations in Sight): Will a Phase 3 Trial Be Initiated?
7.5.3 TriLipix (Abbott): No New Development for Promising Drug
7.5.4 iCo-007 Intravitreal Injection (iCo Therapeutics): Phase 2 Enrolment Completed June 2013
7.5.5 Jetrea (ThromboGenics/Novartis): Possibilities in DME?
8. Regional Market Breakdown, 2015-2026
8.1 Which Markets Hold the Most Revenue Growth Potential?
8.2 The US: Leading Market for Retinal Diseases
8.3 Japan: Strong Market Potential
8.4 EU5: Ageing Populations to Drive Market Growth
8.5 BRIC Nations: The Biggest Growth Driver for the Market
9. Qualitative Industry and Market Analysis, 2016-2026
9.1 Strengths: The Most Dynamic Area of the Ophthalmics Market
9.2 Weaknesses: Heavily Dependent on Anti-VEGF Approach
9.3 Opportunities: New Markets and R&D Synergies
9.4 Threats: Prevention and Management Better Than Drug Treatment for Dry AMD and DR?
9.5 Social: Low Diagnosis, Low Compliance
9.6 Technological: Innovation for the Eye
9.7 Economic: Off-Label Treatment and Reimbursement Issues
9.8 Political: The Demography and Diabetes Challenges
10. Research Interviews
10.1 Interview with Dr. Leigh J. Hsu, Vice President, Corporate Development & Strategy, Lpath, Inc.
10.1.1 Major Changes in AMD and Other Retinal Diseases Market
10.1.2 The Landscape of Emerging Markets
10.1.3 Opportunities and Plans of Marken’s Network
10.1.4 DR Market Opportunities
10.2 Interview with Philip G. Ralston, Jr., MacuCLEAR
10.2.1 MC-1101: Progress in Clinical Trials
10.2.2 MC-1101 More Effective in Early to Mid-Range AMD
10.2.3 Partnerships and Expected Launch of MC-1101
11. Report Conclusions
11.1 The Age of Lucentis: Nearing Its Conclusion?
11.2 Lucentis vs. Eylea vs. Avastin: The Three-Way Anti-VEGF Market
11.3 Indications Outside Wet AMD to Gain in Importance
11.4 Dry AMD Market Has Huge Potential
11.5 Fovista Most Prominent Among the Pipeline Candidates
11.6 Retinal Diseases to Continue to Be the Leading Area of Ophthalmics
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Report Evaluation Form
【レポート販売概要】
■ タイトル:黄斑変性症(AMD)及びその他の網膜疾患治療薬の世界市場■ 英文:Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Industry and Market 2016-2026
■ 発行日:2016年2月
■ 調査会社:visiongain
■ 商品コード:VGAIN6041528
■ 調査対象地域:グローバル
- 世界のスピリッツ(蒸留酒)市場のニュース及びイベント動向(2014年7月)Synopsis The report provides a review of the latest news and key events in the global spirits market during July 2014. Summary Using this report, marketers will effectively gain an insight into the latest happenings in the global spirits market throughout the month. The monthly report provides the reader with the top-line data necessary to quickly keep abreast of latest events in the global spirit …
- Penn West Exploration:石油・ガスの開発・生産動向及びコスト分析- Q3, 2013Penn West Exploration Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2013 Summary Penn West Exploration Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source …
- 再生ガラスの世界市場:製品別(カレット、粉砕ガラス、ガラス粉末)、用途別(ボトル&コンテナー、板ガラス、グラスファイバー、ハイウェイビーズ、その他)The global recycled glass market was valued at $3,529.2 million in 2017 and is projected to reach $5,544.9 million by 2025, growing at a CAGR of 5.7% from 2020 to 2025. Recycled Glass are glass obtained after processing of waste glass into usable products. Glass is 100% recyclable and is recycled from readily available domestic materials such as sand, limestone, soda ash, and cullet. . Out of all …
- クラウドセキュリティの世界市場予測(~2022年)Increasing adoption of BYOD and IoT trends is expected to drive the cloud security marketThe cloud security market size is expected to grow from USD 4.09 billion in 2017 to USD 12.73 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 25.5%. The cloud security market is driven by factors, such as increased adoption of Bring Your Own Device (BYOD) and Internet of Things (IoT0 trends, rise i …
- 乳児用フォーミュラのアジア太平洋市場:種類別(乳児用調製乳、フォローオンミルク、特殊ベビーミルク、グローイングアップミルク)、成分別(炭水化物、脂肪、タンパク質、ミネラル、ビタミン、その他)、流通経路別(ハイパーマーケット、スーパーマーケット、薬局/医療店 、専門店、ディスカウントストア、eコマース、その他)Nutrition is one of the most significant factors that influences a child’s development and growth. The baby infant formula market comprises a diversified range of products from various infant formulas to baby food products. Baby infant formula is produced for feeding babies and infants, which are usually under 12 month of age and also it is prepared from liquid or powder. Baby infant formula facil …
- [Updated] 世界の細胞分析(Cell Analysis)市場動向(~2018)The global cell analysis market is a technology-driven market and is marked by the ‘Threat of Obsolescence,’ wherein technologies as well as their adoption by end users changes very rapidly. Hospitals, academic and government institutes, as well as pharmaceutical and biotechnology companies are increasing their focus on using cell analysis as a powerful research tool in research, drug discovery, a …
- Warren Resources, Inc.:石油・ガスの開発・生産動向及びコスト分析- Q3, 2013Warren Resources, Inc. Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2013 Summary Warren Resources, Inc. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential sour …
- スマートグリッド市場レビュー:September 2013Smart Grid Review - September 2013 Summary GlobalData announces the release of its monthly smart grid newsletter for September 2013. The newsletter provides update on the global developments related to smart grid deployment across the globe during the month of August 2013. Scope - Market prospect for companies providing smart grid systems - Key product launch in power grids - Major news and deals …
- 塩化ビニル(VCM)の世界市場動向及び予測2015The present report is an essential resource for a one looking for detailed information on the world vinyl chloride market. The report covers data on global, regional and national markets including present and future trends for supply and demand, prices, and downstream industries. In addition to the analytical part, the report provides a range of tables and figures which all together give a true in …
- HIL(Hardware-in-the-Loop)の世界市場The hardware in the loop market was valued at USD 480.8 million in 2014 and is expected to grow at a CAGR of 9.37% between 2015 and 2020. The growth of this market is propelled by the ability of the HIL technology to help provide high quality output with reduced time and cost. This makes it ideal for use in a wide range of applications areas such as automotive and aerospace, where time to market i …
- アメリカ教育分野におけるビジュアル・アナリティクス市場About Visual Analytics Visual analytics is an emerging field of analytics that involves the use of visualization, data mining, and statistics to handle massive volumes of data. This is done with the help of human judgement by means of visual representations and interaction techniques. In visual analytics, instead of limiting the analysis to predefined metrics to examine data and study relations be …
- 起立性低血圧症(Orthostatic Hypotension):世界の治験レビュー(2015年上半期版)Orthostatic Hypotension Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Orthostatic Hypotension Global Clinical Trials Review, H1, 2015" provides data on the Orthostatic Hypotension clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Orthostatic Hypotension. It includes an overview of the trial numbers …
- フレークアイス製氷機の世界市場2017-2021About ice flakerAn ice flaker is a continuous-type ice maker that freezes and dispenses irregular bits of ice simultaneously. Flake ice can be either scale or granular ice. Most flake machines use a stationary evaporator. Flake ice is constantly scraped from the evaporator walls of the ice making machine by a slowly rotating auger. Technavio’s analysts forecast the global ice flaker market to grow …
- 世界のBFSI(銀行・金融サービス・保険)セキュリティ市場:物理的セキュリティ、サイバーセキュリティOver the last few decades, the operating environment of BFSI industry has changed significantly in terms of technological advancements and work flow processes. There has been continuous technological revolution in the banks and financial institutions in the form of ATMs, core banking, e-banking, mobile banking, and consequently many services came into existence such as Real Time Gross Settlement ( …
- サージ防護機器の世界市場2015-2019About Surge Protection Device Sudden increase in voltage significantly above the designated level in the flow of electricity is termed as power surge. These sudden spikes in the flow of electricity are harmful to appliances. It can damage machines after frequent surges or immediately. Surge suppressor devices protect electrical appliances from getting damaged by diverting the extra electricity gen …